A new treatment to improve ovarian cancer therapy effectiveness
Official title: The SIK2 Inhibitor GRN-300 Enhances PARP Inhibitor Sensitivity and Cytotoxic T-Cell Function in Ovarian Cancer
Funded at University of Tx Md Anderson Can Ctr · NIH-11161652 · Data updated 2026-11-12
This study is testing a new drug called GRN-300 to see if it can make existing ovarian cancer treatments work better, especially for patients whose cancer hasn't responded well to standard therapies.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | September 19, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $177,085 |
| NIH project number | 3P50CA281701-02S1 |
| Project ID | NIH-11161652 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are women diagnosed with ovarian cancer, particularly those who have not responded well to standard treatments or have specific genetic mutations.
✕Less likely to help
Patients with early-stage ovarian cancer who have not yet undergone treatment may not benefit from this research.
What this research studies
This research investigates the use of a novel drug, GRN-300, which targets a specific protein to enhance the effectiveness of existing ovarian cancer treatments, particularly carboplatin and paclitaxel. The study includes a first-in-human trial to determine the safest dose of GRN-300 when used alone and in combination with weekly paclitaxel. Additionally, it explores how GRN-300 can increase the sensitivity of ovarian cancer cells to another treatment called olaparib, especially in cases where the cancer has developed resistance to standard therapies. By understanding the mechanisms of how GRN-300 works, the research aims to improve treatment outcomes for patients with ovarian cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for ovarian cancer patients, potentially improving survival rates and quality of life.
How similar studies have gone: Previous research has shown promising results with similar approaches, indicating potential for success in enhancing treatment efficacy for ovarian cancer.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Bast, Robert C — University of Tx Md Anderson Can Ctr
- Study coordinator: Bast, Robert C
Related research
Other NIH-funded projects on the same topics.
-
Understanding the experience of ovarian cancer after diagnosis to improve survivorship
This NIH grant funds a mixed-methods study to better understand physical and emotional challenges faced by ovarian cancer survivors and how supportive care can help them live better after diagnosis.
-
Targeting quiescent ovarian cancer cells to overcome chemotherapy resistance
A study focusing on why some ovarian cancer cells pause dividing and resist chemotherapy, with the goal of finding new treatment targets for relapsed disease.
-
Photodynamic lipids to boost chemotherapy for metastatic ovarian cancer
A patient-friendly approach tests a light-activated method to make ovarian cancer metastases more sensitive to chemotherapy.
-
Integrated framework to validate and quantify proteoforms in patient-derived ovarian cancer cells
A collaboration will combine advanced top-down proteomics with a new computational method to precisely identify and measure intact proteoforms in tiny samples from ovarian cancer cells.
-
Overcoming platinum resistance in ovarian cancer: finding biomarkers and new targets
Researchers are looking for new biomarkers and targets to help prevent or overcome platinum resistance in high‑risk ovarian cancer so patients have better chances at long-term control.
-
Alternative NF-kB activation after chemotherapy in ovarian cancer
This grant studies how ovarian cancer might come back after chemotherapy by looking at specific signaling pathways in cancer cells and the tumor environment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.